【摘要】 目的:检测胶质瘤患者血浆中IGFBP-6的浓度,探讨其作为临床预测脑胶质瘤生存期标志物的可能性。方法:用酶联免疫吸附法(ELIISA)检测207例不同级别胶质瘤患者和36例正常对照者的血浆IGFBP6水平。采用方差分析(analysis of variance,ANOVA)比较胶质瘤患者与正常对照组及不同分级的胶质瘤患者的血浆IGFBP6水平,及对中位生存期的影像。结果:(1)低级别胶质瘤(Ⅱ级)患者血浆IGFBP-6平均水平(154.95±43.02ng/mL)较正常对照组(188.77±59.57ng/mL)明显降低(P<0.05),亦明显低于高级别胶质瘤(Ⅲ,Ⅳ级)(183.14.95±71.43ng/mL)(P<0.05),而高级别胶质瘤和正常对照之间无显著性差异。(2)Ⅲ级胶质瘤患者低血浆IGFBP6水平组生存期均值为711天(中位生存期,788天,95%CI,618-805)与高血浆IGFBP6水平组577天(中位生存期,607天,95%CI,510-644)相比有显著统计学差异(P<0.001)。结论:血浆IGFBP-6水平具有成为脑胶质瘤标记物的潜质,可能作为一个生物标记物来预测患者的生存期。更多还原

【Abstract】 Objective:To investigate the possibility of insulin-like growth factor binding protein 6(IGFBP6) as a potential prognosis predicator in the patients with cerebral glioma and the pathological grading value of its plasma concentration. Methods:IGFBP-6 ELISA kit was used to measure the plasma IGFBP-6 concetrtion of 207 patients who had been newly diagnosed with cerebral glioma and 36 healthy volunteers. Grade Ⅲ glioma patients whose pathological tissue contained astrocytoma were compared. Results:(1)The preoperative plasma IGFBP-6 levels could significantly discriminate the surviwal of the two grade Ⅲ glioma subgroups,with a mean survival time of 711days(the mean survival time, 788days, 95% CI,618-805) in low plasma IGFBP-6 level group versus mean survival time of 577days(the mean survival time, 607days,95%CI,510-644) in high plasma level group(P<0.001).(2)Plasma IGFBP-6 levels were significantly higher in patients with high-grade glioma(183.14.95±71.43ng/mL)and healthy controls(188.77±59.57 ng/mL) than in patients with low-grade glioma(154.95±43.02ng/mL)(P<0.05); And no obvious difference of plasma IGFBP-6 levels was found between high-grade glioma patients and healthy controls. Conclusions: Plasma IGFBP-6 levels have the potential predictor value as a biomarker for pathological grading and follow-up of progression and survival in-grade Ⅲ gliomas. Larger and broader population with an extended follow-up is needed to further validate these findings.更多还原